MET and non-small cell lung carcinoma: Merestinib (LY2801653) is a multikinase inhibitor that can inhibit MET, ROS1, and AXL, and an ongoing phase II clinical trial (NCT02920996) involving NSCLC patients harboring METex14 skipping mutations84.